APS Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$33,204.19
Insider Selling (Last 12 Months): C$0.00

Aptose Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Aptose Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aptose Biosciences Share Price & Price History

Current Price: C$0.95
Price Change: Price Decrease of -0.01 (-1.04%)
As of 12/5/2022 04:29 PM ET

This chart shows the closing price history over time for APS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Aptose Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/19/2022William Glenn RiceDirectorBuy5,700C$0.88C$5,025.04358,952
6/6/2022William Glenn RiceDirectorBuy2,776C$1.22C$3,375.69346,028
12/20/2021Denis BurgerDirectorBuy10,000C$1.87C$18,692.1031,671
12/16/2021William Glenn RiceDirectorBuy3,183C$1.92C$6,111.36333,252
11/26/2021William Glenn RiceDirectorBuy1,000C$3.07C$3,069.00304,604
11/19/2021Rafael BejarSenior OfficerBuy10,000C$3.38C$33,792.0010,000
6/21/2021Warren WhiteheadDirectorSell15,400C$4.15C$63,848.4024,600
12/22/2020Warren WhiteheadDirectorSell10,000C$5.17C$51,745.0050,000
7/10/2020Gregory Kwok Lee ChowSenior OfficerSell126,668C$8.47C$1,072,877.96232,846
7/10/2020William Glenn RiceDirectorSell168,891C$8.47C$1,430,506.77297,523
6/23/2020Warren WhiteheadDirectorSell5,000C$9.69C$48,450.0058,000
See Full Table
Top Innovation Stock
Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.
Click here for the name and ticker

SEC Filings (Institutional Ownership Changes) for Aptose Biosciences (TSE:APS)

Aptose Biosciences logo
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More on Aptose Biosciences

Today's Range

Now: C$0.95
Low: C$0.94
High: C$0.95

50 Day Range

MA: C$0.81
Low: C$0.63
High: C$1.03

52 Week Range

Now: C$0.95
Low: C$0.62
High: C$2.72


1,560 shs

Average Volume

26,651 shs

Market Capitalization

C$87.68 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Aptose Biosciences?

Aptose Biosciences' top insider investors include:
  1. William Glenn Rice (Director)
  2. Warren Whitehead (Director)
  3. Denis Burger (Director)
  4. Rafael Bejar (Senior Officer)
Learn More about top insider investors at Aptose Biosciences.